UK settles for interim PPRS, for now
This article was originally published in Scrip
A new pharmaceutical price regulation scheme for the UK has yet to be decided. Although significant progress has been made on a voluntary scheme starting in January 2009, negotiations continue on the details, the Department of Healthand the Association of the British Pharmaceutical Industryhave said.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
European biotech Pharvaris has received series C funding to support its novel potential therapy for hereditary angioedema, in a competitive sector of drug development.
Top-line results from BrainStorm’s NurOwn Phase III ALS study show the cell therapy missed the primary efficacy endpoint, but clinically meaningful responses were seen in a pre-specified subgroup which investigators considered potentially a significant step forward in therapy.